Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder Inhalation Aerosol Delivery by Wu, Xiao et al.
Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
University of Kentucky 
UKnowledge 
Pharmaceutical Sciences Faculty Publications Pharmaceutical Sciences 
3-2013 
Physicochemical Characterization and Aerosol Dispersion 
Performance of Organic Solution Advanced Spray-Dried 
Cyclosporine A Multifunctional Particles for Dry Powder 
Inhalation Aerosol Delivery 
Xiao Wu 
University of Kentucky, xiao.wu@uky.edu 
Weifen Zhang 
University of Kentucky 
Don Hayes Jr. 
Ohio State University 
Heidi M. Mansour 
University of Kentucky, heidi.mansour@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Physicochemical Characterization and Aerosol Dispersion Performance of Organic 
Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder 
Inhalation Aerosol Delivery 
Notes/Citation Information 
Published in International Journal of Nanomedicine, v. 8, no. 1, p. 1269-1283. 
Copyright © 2013 Wu et al, publisher and licensee Dove Medical Press Ltd. This is an Open 
Access article which permits unrestricted noncommercial use, provided the original work is 
properly cited. 
Digital Object Identifier (DOI) 
http://dx.doi.org/10.2147/IJN.S40904 
This article is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/15 
© 2013 Wu et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2013:8 1269–1283
International Journal of Nanomedicine
Physicochemical characterization and aerosol 
dispersion performance of organic solution 
advanced spray-dried cyclosporine A multifunctional 





1Department of Pharmaceutical 
Sciences – Drug Development 
Division, University of Kentucky, 
Lexington, KY, USA; 2College of 
Pharmacy and Biological Science, 
Weifang Medical University, 
Weifang, People’s Republic of 
China; 3Department of Pediatrics, 
4Department of Internal Medicine, 
The Ohio State University College 
of Medicine, Nationwide Children’s 
Hospital Lung and Heart-Lung 
Transplant Program, 5Davis Heart 
and Lung Research Institute, The 
Ohio State University, Columbus, 
OH, 6Center of Membrane Sciences, 
University of Kentucky, Lexington, 
KY, USA
Correspondence: Heidi M Mansour 
University of Kentucky, College of 
Pharmacy, Department of Pharmaceutical 
Sciences – Drug Development Division, 
789 S Limestone Street, Lexington,  
KY 40536-0596, USA 
Tel +1 859 257 1571 
Fax +1 859 257 7564 
Email heidi.mansour@uky.edu
Abstract: In this systematic and comprehensive study, inhalation powders of the polypeptide 
immunosuppressant drug – cyclosporine A – for lung delivery as dry powder inhalers (DPIs) 
were successfully designed, developed, and optimized. Several spray drying pump rates were 
rationally chosen. Comprehensive physicochemical characterization and imaging was carried 
out using scanning electron microscopy, hot-stage microscopy, differential scanning calorimetry, 
powder X-ray diffraction, Karl Fischer titration, laser size diffraction, and gravimetric vapor 
sorption. Aerosol dispersion performance was conducted using a next generation impactor 
with a Food and Drug Administration-approved DPI device. These DPIs displayed excellent 
aerosol dispersion performance with high values in emitted dose, respirable fraction, and fine 
particle fraction. In addition, novel multifunctional inhalation aerosol powder formulations of 
cyclosporine A with lung surfactant-mimic phospholipids were also successfully designed and 
developed by advanced organic solution cospray drying in closed mode. The lung surfactant-
mimic phospholipids were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-
glycero-3-(phosphor-rac-1-glycerol). These cyclosporine A lung surfactant-mimic aerosol 
powder formulations were comprehensively characterized. Powder X-ray diffraction and 
differential scanning calorimetry confirmed that the phospholipid bilayer structure in the solid 
state was preserved following advanced organic solution spray drying in closed mode. These 
novel multifunctional inhalation powders were optimized for DPI delivery with excellent aerosol 
dispersion performance and high aerosol performance parameters.
Keywords: dry powder inhaler (DPI), polypeptide drug, lung surfactant, calcineurin inhibitor, lung 
immunosuppression, dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylglycerol 
(DPPG), targeted lung immunosuppression
Introduction
Cyclosporine A (CsA) is a lipophilic (hydrophobic), cyclic undecapeptide, and a high 
molecular weight polypeptide immunosuppressant drug.1–3 As a calcineurin inhibitor, 
CsA reversibly inhibits T-cell mediated immune response, including the synthesis of 
interleukin-2, interleukin-6, and interferon-γ.3 As a calcineurin inhibitor, it blocks lym-
phocyte activation by inhibiting transcription of cytokine genes in a dose-dependent 
manner.1–3 In addition, CsA has therapeutic effects on the prevention of allograft rejection 
after lung transplantation.4,5 The systemic effects associated with CsA are substantial, 
including hypertension and most notably renal toxicity.6 Local noninvasive administra-
tion of CsA as aerosols may reduce the incidence of toxic complications associated with 
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systemic administration of CsA, increase the therapeutic avail-
ability of CsA for localized immunosuppression, and provide 
a high pulmonary concentration.7–9 Local pulmonary delivery 
of CsA as nebulized liquid aerosols in lung transplant patients 
has been reported.10,11 The improved response in a lung 
transplant patient by inhaled nebulized tacrolimus, another 
important immunosuppressant drug, for successful lung 
immunosuppression while significantly reducing systemic 
side effects and improving patient outcomes has been recently 
reported by the authors’ group.12 A metered-dose inhaler of 
CsA has been aerosolized in asthmatic patients.8 A nebulized 
liquid aerosol of CsA encapsulated in liposomes composed 
of nonionic surfactants and phospholipids,13 inhaled CsA 
dry powders produced by wet-milling,14 and inhaled CsA 
inulin-based dry powders produced by spray freeze drying 
from a tert-butyl alcohol/water cosolvent  system15 have been 
reported. Recently, CsA nanosuspensions containing mannitol 
(ie, a water-soluble sugar) produced by antisolvent precipita-
tion followed by aqueous solution spray drying (SD) generated 
inhalable CsA mannitol powders.16 In addition, evaporative 
precipitation into aqueous solution has been reported to 
produce CsA nanoparticles possessing low crystallinity for 
oral and/or parenteral delivery with enhanced bioavailability 
resulting from high dissolution rates.17
Dry powder inhalers (DPIs) of CsA are a targeted delivery 
option for direct administration of CsA to the lung. Targeted 
delivery of a wide array of pulmonary drugs directly and 
efficiently to the lungs has been reported,12,18–21 and with 
high patient acceptance. DPIs offer many advantages such 
as improved stability, higher dose delivery, and better control 
of aerosol particle properties.19,22–25 Performance of inhaled 
aerosols are influenced by the physicochemical properties of 
the inhaled particles including particle size, size distribution, 
particle morphology, surface morphology, and residual water 
content.19,22–24,26 Inhaled particles with a particle size in the 
range of 400 nm to 5 µm can efficiently target the smaller 
airways and deep lung regions.19,20,22,23,27
Pulmonary surfactant is secreted by the type II pneumo-
cytes in the lining of the alveoli. It is comprised of a mix-
ture of specific phospholipids and lung surfactant-specific 
 proteins. It has a vital role in reducing the work of breathing 
by reducing the surface tension to near 0 mN/m at the air/
water interface in the lung.28–31 The main constituents of 
pulmonary surfactant are lipids and lung  surfactant-specific 
proteins, which account for ∼90% and 10% of the surfactant 
mass, respectively.32,33 Of the lipids, ∼85%–90% are specific 
phospholipids, of which ∼80% are phosphatidylcholine 
and ∼10% are phosphatidylglycerol.28,30,33 The fraction of 
phosphatidylcholine accounted for by dipalmitoylphos-
phatidylcholine (DPPC), a disaturated 16-carbon acyl 
chain phosphatidylcholine, is 54% in humans.34 The lung 
surfactant-mimic phospholipids – DPPC and dipalmi-
toylphosphatidylglycerol (DPPG) – are used in lung surfac-
tant replacement therapies, controlled release drug delivery, 
liposomal drug delivery, and phospholipid colloidal carrier 
nanomedicine pulmonary delivery.25,27,30,35–38 Novel DPIs 
containing phospholipids as multifunctional biocompatible 
excipients offer several unique advantages, as described 
in detail by the authors’ group.25 It has been demonstrated 
that phospholipids improve migration of particles to the 
lung periphery by spreading due to the reduction in surface 
tension provided by their surface chemistry.27–30,35,39 DPPC 
and DPPG phospholipids are innate to the lung, and hence 
are inherently biocompatible and biodegradable in the 
lung. These phospholipids may also facilitate drug absorp-
tion by improving wettability. In nanopharmaceuticals, 
 phospholipids self-assemble to form colloidal nanocarri-
ers.27,35–38 Novel DPIs for pulmonary nanomedicine delivery 
composed of respirable microparticulate/nanoparticulate dry 
powders of DPPC/poly(ethylene glycol) (PEG)ylated phos-
pholipid systems40 and tacrolimus inhalation powders41 have 
been recently reported by the authors’ group. Respiratory 
delivery of CsA incorporated in biocompatible biodegrad-
able lung surfactant-mimic DPPC/DPPG in the solid state as 
DPI aerosols would facilitate CsA delivery, with high local 
concentration in the smaller airways of the lung.
This systematic and comprehensive study reports for the 
first time the rational design, physicochemical characteriza-
tion, and optimization of novel therapeutic aerosols as DPIs 
of respirable CsA microparticles and nanoparticles for tar-
geted DPI delivery for lung transplant  immunosuppression. 
The novel engineering high-throughput process of organic 
solution advanced SD in closed mode was employed, as 
reported by the authors for the first time for pulmonary 
delivery inhalation applications.40–42 In addition, this study 
reports for the first time the rational design, physicochemi-
cal characterization, and high-throughput optimization of 
novel DPIs consisting of CsA with lung surfactant-mimic 
DPPC/DPPG phospholipids as dry powder microparticulate/ 
nanoparticulate aerosols designed by advanced organic 
solution co-SD in closed mode.
Material and methods
Materials
CsA US Pharmacopeia grade (Spectrum Chemical Mfg 
Corp, New Brunswick, NJ, USA) has a molecular weight of 
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1202.61 g/mol. Methanol (high-performance liquid chroma-
tography grade, American Chemical Society certified, 0.2 µm 
filtered) was used for all SD experiments and was purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). 
Synthetic lung surfactant-mimic phospholipid powders, 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (ie, DPPC) 
and 1,2-dipalmitoyl-sn-glycero-3-(phosphor-rac-1-glycerol) 
sodium salt (ie, DPPG), were purchased from Avanti Polar 
Lipids Inc (Alabaster, AL, USA). AQUASTAR® anhydrous 
methanol 99.8% was obtained by EMD Chemi cals, Inc 
(Darmstadt, Germany). Hydranal®-Coulomat AD was from 
Sigma-Aldrich (St Louis, MO, USA). All powders were 
stored in tightly sealed glass desiccators over Drierite®/
Indicating Drierite® (W A Hammond Drierite Co, Ltd, Xenia, 
OH, USA) desiccant in the freezer at −23°C.
Preparation of SD CsA and co-SD CsA: 
DPPC/DPPg particles from organic 
solution advanced SD in closed mode
Solutions containing CsA were prepared with a total powder 
mass of 1% (weight/volume) in methanol. The prepared 
formulations were subsequently SD using the Buchi mini 
SD B-290 with a Buchi high-performance cyclone plus the 
Buchi inert loop B-295 (Buchi Labortechnik AG, Flawil, 
Switzerland) in closed mode under ultra high purity (UHP) 
nitrogen gas (Scott-Gross Company, Inc, Winchester, KY, 
USA). As stated in Table 1 and similar to the advanced SD 
conditions previously reported by the current authors,40,42 
the following SD conditions in closed mode were used: inlet 
temperature, 100°C; UHP nitrogen atomizing gas flow 601 L/
hour; various pump rates rationally selected; and aspirator 
setting, 100%. The four SD pump rates were rationally chosen 
at 10% (low), 25%, 50% (medium), and 75% (high).
Co-SD CsA powders of CsA lung surfactant lipospheres 
were prepared by dissolving DPPC, DPPG, and the drug 
simultaneously in methanol with a total powder mass of 1% 
(w/v) followed by co-SD under optimized SD conditions 
(50% pump rate). The molar ratio of DPPC:DPPG was 3:1, 
as this is a lung surfactant-mimic ratio. The advanced co-SD 
process was operated under the conditions described above. 
All SD and co-SD powders were stored in a desiccator in 
the freezer until analysis.
Laser diffraction particle size  
and size distribution
Using similar conditions as previously reported,42–45 the 
primary particle size in the solid state and size distribution 
were measured by an ultraviolet laser diffraction nanopar-
ticle size analyzer (SALD-7101; Shimadzu Corporation, 
Kyoto, Japan). The measured sample was prepared by 
dispersing ∼40 mg powder in 10 mL deionized water in a 
capped vessel and then gently shaking. Prior to each measure-
ment, background measurements were carried out by using 
a blank cell filled with deionized water. Then, 1.5 mL of the 
sample was added to the blank for measurement. The refrac-
tive index of the measured samples was 1.60–0.10.
Scanning electron microscopy (SEM)
Using similar conditions as previously reported,40,42–45 the 
shape and surface morphology of all raw, SD, and co-SD 
powders were investigated by SEM (S-800; Hitachi Ltd, 
Tokyo, Japan). Each sample was fixed on an aluminum 
specimen stub covered with a double-sided adhesive carbon 
disc, and then sputter coated (Hummer VI Sputtering System; 
Technics, Anatech USA, Union City, CA, USA) with gold 
prior to imaging. Sputter coating was performed at 20 mA 
for 3 minutes.
Differential scanning calorimetry (DSC)
Using similar conditions as previously reported,28–30,40,42–46 
DSC was performed by using model Q200™ equipped with 
an automated computer-controlled refrigerated cooling system 
(RSC-90) and Tzero™ capabilities (TA Instruments, New 
Castle, DE, USA). The DSC thermograms were collected 
using a sample weight of 3–5 mg powder and placed in 
Tzero alodine-coated aluminum DSC pans, which were then 
hermetically sealed with a Tzero hermetic sealer (TA Instru-
ments). The phase transition temperatures – melting point (T
m
) 
– of the samples were measured under a 50 mL/minute dry 
UHP nitrogen gas (Scott-Gross) purge in DSC. The samples 
were heated at 5°C/minute from 10°C to 300°C. At least four 
melting scans were carried out to ensure T
m
 reproducibility. 
The measured DSC data were analyzed using a coupled DSC 
Q200-1740 data station (TA Instruments).
Table 1 Spray drying parameters of four pump rates, inlet 
temperature, and the corresponding outlet temperature in the 
spray drying process of dilute organic solution advanced spray-
dried cyclosporine A dry powder inhalers






SD CsA 10%P 10 100 53
SD CsA 25%P 25 100 43
SD CsA 50%P 50 100 30
SD CsA 75%P 75 100 22
Abbreviations: %P, pump rate; CsA, cyclosporine A; SD, spray dried.
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X-ray powder diffraction (XRPD)
Using similar conditions as previously reported,30,40,42–45 the 
degree of long-range molecular order (crystallinity) versus 
disorder (noncrystallinity) for all powders was measured 
by XRPD. The XRPD pattern was collected with a Rigaku 
Multiflex X-ray diffractometer (Rigaku Corporation, Tokyo, 
Japan) with a slit detector copper Kα source at 44 mA and 
40 kV. CsA samples were gently pressed onto a glass slide 
(Rigaku) to form a level surface. The glass slide was then 
placed in the X-ray beam path. Data were obtained from 5–60 
2θ degrees at room temperature at a scanning rate of 2 2θ 
degrees/minute and a step rate of 0.04 2θ degrees.
Cross-polarizing light hot-stage microscopy
Using similar conditions as previously reported,40,42 solid-state 
phase transitions for raw CsA, SD CsA, and co-SD CsA lung 
surfactant-mimic phospholipid powders were observed under 
cross-polarizing light hot-stage microscopy (HFM) for the 
presence and/or absence of birefringency. The polarized opti-
cal microscope (BX51; Olympus Corporation, Tokyo, Japan) 
and a hot stage were equipped with a temperature control unit 
(STC200; Instec Inc, Boulder, CO, USA). The microscope 
was connected to a computer and SPOT Advanced™ software 
(Diagnostic Instruments, Inc, Sterling Heights, MI, USA) was 
used to capture pictures from the microscope. The temperature 
control unit was also connected to a computer and WinTemp 
2.00 software (Instec Inc., Boulder, CO, USA) was used to 
set up the heating conditions. Samples were mounted on a 
microscope glass slide and placed into the sample chamber of 
the hot stage. Samples were then heated from 25°C to a final 
temperature of 200°C at a step rate of 5°C/minute.
Circular dichroism (CD) spectroscopy
Using similar conditions as previously reported,30 CD mea-
surements were carried out on model J-810 Spectropolarim-
eter (Jasco, Inc, Easton, MD, USA). CsA was dissolved in 
methanol at a concentration of 100 µM. The scanning wave-
length range was 195–250 nm in 0.5 nm increments. Nitrogen 
gas was supplied to prevent the accumulation of oxygen in the 
system, which produces CD absorption bands around 200 nm. 
Other parameters were the following: data pitch: 0.5 nm; scan 
speed: 50 nm/minute; response time: 8 seconds; accumulation: 
four; and band width: 1 nm. The baseline spectrum of the 
solvent alone was taken prior to sample measurements.
Karl Fischer coulometric titration
Using similar conditions as previously reported,40,42,46 residual 
water content in the DPI aerosol powders was analytically 
quantified by Karl Fischer coulometric titration method using 
a Karl Fischer titrator cell (737 KF Coulometer; Metrohm AG, 
Herisau, Switzerland) equipped with a magnetic stirring device 
(703 Ti Stand; Metrohm). Karl Fischer titrator was filled with 
Hydranal-Coulomat AD reagent, comprising of methanol, 
diethanolamine, imidazole, hydroiodic acid, and sulfur diox-
ide. The powder sample was prepared by dissolving 50 mg of 
powder into 100 mL AQUASTAR anhydrous methanol. The 
precisely weighed sample solution (∼500 mg) was then injected 
into Karl Fischer titrator to react with titration reagent under 
magnetic stirring. At the end point of titration, the water amount 
in the analyzed CsA sample was displayed automatically on the 
titrator. Given that the weight of reacted sample was known, the 
percentage of water in the sample was calculated.
gravimetric water vapor sorption
Using similar conditions as previously reported,30,42,46 
 gravimetric water vapor isotherms were measured using 
a Cahn® automated ultrasensitive microelectronic balance 
coupled to a computerized SGA-CX Symmetrical Gravimetric 
Analyzer (VTI Corporation, Hialeah, FL, USA) under dry 
UHP nitrogen gas vacuum conditions. All measurements were 
made at 25°C using a sample size of 1.5–2.5 mg. Before the 
absorption step, samples were dried in situ under dry UHP 
nitrogen gas vacuum conditions. The criterion used to establish 
drying equilibrium was a weight change of 0% in a 10-minute 
interval. At the end of the drying cycle, the sample was exposed 
to a sequence of increasing relative humidity (RH) levels under 
equilibrium conditions starting at 0% RH. Data were logged 
every 2 minutes or when weight gain reached 0.01%. Up to 
a maximum of 3 hours was allowed, which was sufficient to 
reach absorption equilibrium at each RH level. The criterion 
used to establish absorption equilibrium was a weight change 
of #0.03% in a 10-minute interval.
In vitro aerosol dispersion performance 
by the next generation impactor (NgI)
The US Pharmacopeia describes the specifications on aero-
sols performance47 and, as previously reported,40 the aerosol 
dispersion performance was tested using inertial impaction. 
The aerosol dispersion properties of the dry powder particles 
as DPIs were determined using the NGI with a stainless steel 
induction port (ie, US Pharmacopeia throat) attachment 
(170 NGI™; MSP Corporation, Shoreview, MN, USA), 
equipped with specialized stainless steel NGI gravimetric 
insert cups (MSP Corporation). A DFM 2000 flow meter 
(Copley Scientific, Nottingham, UK) was employed to mea-
sure and adjust the airflow rate (Q) prior to each  experiment. 
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The NGI was coupled with a TPK 2000 critical flow control-
ler (Copley) that was connected to an HCP5 vacuum pump 
(Copley). The NGI was operated at a controlled flow rate of 
Q = 60 L/minute. For the NGI Q = 60 L/minute, the effective 
cutoff diameters for each impactor stage were calibrated by the 
manufacturer and stated as follows: stage one (8.06 µm); stage 
two (4.46 µm); stage three (2.82 µm); stage four (1.66 µm); 
stage five (0.94 µm); stage six (0.55 µm); and stage seven 
(0.34 µm).
The aerosolization studies were experimentally 
designed by Design-Expert® 8.0.7.1 software (Stat-Ease, 
Inc,  Minneapolis, MN, USA). Glass fiber filters (Type A/E, 
55 mm; Pall Corporation, Port Washington, NY, USA) were 
placed in the stainless steel NGI gravimetric insert cups 
for NGI stages one through seven to minimize bounce or 
 reentrapment. Three hydroxypropyl methylcellulose hard 
capsules (size three, Quali-V®; Qualicaps, Irving, TX, 
USA) were each loaded with 10 mg powder, which were 
then loaded into a high resistance (ie, high sheer stress) 
human DPI device  (HandiHaler®; Boehringer Ingelheim 
GmbH, Ingelheim, Germany), and tightly inserted into the 
induction port. Three capsules (containing 10 mg of aerosol 
formulation per capsule) were used per aerosol experiment 
run. For each aerosol experiment run, the mass of particles 
deposited onto each stage was determined gravimetrically 
by measuring the difference in mass of the glass filters after 
particle deposition.
The mass mean aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) were calculated using 
a mathematic program written by Dr Jay Holt.48 All experi-
ments were triplicated (n = 3). The fine particle dose, fine 
particle fraction (FPF), respirable fraction (RF), and emitted 
dose (ED) were calculated as follows:
Fine particle dose =  Mass of particles , 4.46 µm  
(stages two through seven)
 FPF
Fine particle dose
Initial particle mass loaded into capsules
= × 100%
RF
mass  of particles <448 m stages two through seven)
tot
= µ (




Initial mass in capsules Final mass remaining in capsul= − es
Initial mass in capsules
× 100%
Data and statistical analyses
The results were analyzed statistically using Prism® 4 soft-
ware (GraphPad Software, Inc, La Jolla, CA, USA). The 
results are expressed as mean ± standard deviation. An 
unpaired Student’s t-test and one-way analysis of variance 
were used to compare the means and to assess statistical 
significance. Results were considered statistically significant 
if P , 0.001. The aerosolization studies were experimentally 
designed using design of experiments by Design-Expert 
8.0.7.1 software (Stat-Ease).
Results
Laser diffraction particle size  
and size distribution
Table 1 provides a summary of the CsA samples investi-
gated in the current study. During the SD process, when the 
operating parameters – including nozzle orifice, atomization 
pressure, feed solvent, feed concentration, inlet temperature, 
and spray gas flow rate remained constant – different pump 
rates resulted in different outlet temperatures, which is to be 
expected (Table 1).
In laser diffraction analysis of SD CsA at rationally cho-
sen pump rates (Table 2), the Dv
10
 volumetric particle size 
range over the range of pump rates was 0.81–1.16 µm, the 
Dv
50
 volumetric particle size range over the range of pump 
rates was 0.95–1.41 µm, and the Dv
90
 volumetric particle 
size range over the range of pump rates was 2.91–3.79 µm. 
A correlation was observed in which increasing the SD 
pump rate of drug organic solution yields particles with 
a slightly larger particle size. The particle size distribu-
tion for the SD CsA aerosol powders was unimodal and 
narrow, which is important for enhancing reproducible 
aerosol delivery.
Table 3 lists the compositions of co-SD CsA lung 
surfactant-mimic liposphere aerosol powder formulations 
designed in this study. In laser diffraction analysis, the 
mean Dv
50
 sizes of co-SD CsA:DPPC/DPPG 25:75 and 
co-SD CsA:DPPC/DPPG 75:25 were 1.49 µm and 1.73 µm, 
respectively (Table 3). The particle size distribution of the 
co-SD CsA:DPPC/DPPG lung surfactant-mimic particles 
was unimodal and narrow, which is important for reproduc-
ible aerosol delivery.
SEM
The particle morphology, surface morphology, and primary 
particle size of raw unprocessed CsA and SD CsA DPI aerosol 
formulations were imaged and the SEM micrographs are shown 
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Table 2 Volumetric particle size (Dv10, Dv50, and Dv90), particle shape, and surface morphology properties of spray-dried cyclosporine A 
dry powder inhalation powders from different pump rates
Sample Volumetric particle  
size Dv10, μm
Volumetric particle  
size Dv50, μm






SD CsA 10%P 0.81 ± 0.03 0.95 ± 0.09 2.91 ± 0.18 Sphere Corrugated
SD CsA 25%P 0.94 ± 0.04 1.12 ± 0.08 3.10 ± 0.22 Sphere Corrugated
SD CsA 50%P 0.99 ± 0.01 1.33 ± 0.10 3.47 ± 0.15 Sphere Corrugated
SD CsA 75%P 1.16 ± 0.03 1.41 ± 0.08 3.79 ± 0.31 Sphere Smooth
Notes: Mean ± standard deviation, n = 5.
Abbreviations: %P, pump rate; CsA, cyclosporine A; SD, spray dried.
Table 3 Compositions and average volumetric particle size (Dv50) of cospray-dried cyclosporine A: dipalmitoylphosphatidylcholine/
dipalmitoylphosphatidylglycerol lung surfactant-mimic dry powder inhalation aerosol formulations by advanced cospray drying from 
organic solution
co-SD CsA: (DPPC/DPPG)  
sample abbreviation
CsA content,  
mole %




co-SD CsA lipo 25:75 (1:3) 25 75 1.49 ± 0.16
co-SD CsA lipo 75:25 (3:1) 75 25 1.73 ± 0.08
Notes: Mean ± standard deviation, n = 5.
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; DPPg, dipalmitoylphosphatidylglycerol; lipo, lipospheres; SD, spray dried.
in Figure 1. As can be seen, the raw CsA are too large for inha-
lation with irregular nonspherical morphology (Figure 1A). 
SD CsA aerosol powders prepared at 10%  (Figure 1B), 25% 
(Figure 1C), and 50% (Figure 1D) pump rates are observed 
as spherical particles with a corrugated surface, while SD 
CsA at a 75% pump rate (Figure 1E) is observed as spherical 
particles with a smooth surface. Particle dimensions of all SD 
batches appear much smaller than that of raw CsA and are in 
excellent agreement with those measured by laser diffraction 
particle sizing (Table 2). The particle morphology and surface 
morphology are summarized in Table 2.
The SEM micrograph of raw CsA and co-SD CsA lung 
surfactant-mimic lipospheres are shown in Figure 2. The raw 
unprocessed CsA (Figure 2A) have an irregular nonspherical 
morphology with very large dimensions that are much too 
large for inhalation. The co-SD CsA lung surfactant-mimic 
liposphere particles (Figures 2B and C) appear as spherical 
particles with a smooth surface morphology. The particle 
size of co-SD CsA:DPPC/DPPG lung surfactant-mimic 
particles observed in their SEM images is in excellent agree-
ment with that measured by laser diffraction particle sizing 
(Table 3) and much smaller than that of raw CsA, making 
them within the inhalable size range for targeted pulmonary 
delivery as DPIs.
DSC
The DSC thermograms of raw CsA versus SD CsA aerosol 
powders are shown in Figure 3. Raw CsA was characterized 
by a sharp narrow endothermic phase transition peak, which 
had an onset temperature at ∼161°C. The melting of crys-
talline CsA is similar to that reported in the literature.49,50 
This order-to-disorder endothermic peak can be attributed 
to melting. These observations are in good agreement with 
previous reports on crystalline CsA, indicating the crystalline 
nature of the raw drug. Similarly, the thermograms of SD 
CsA aerosol powders at a 10%, 25%, 50%, and 75% pump 
rate showed endothermic peaks with onset temperatures of 
∼152°C, 162°C, 153°C, and 154°C, respectively. The peaks 
that represent the SD samples correspond to those of the 
original CsA but differ in intensity (peak broadness), sug-
gesting that the SD process has rendered the final powder in 
a different state from the raw as is often observed in SD.
The thermograms of raw CsA and co-SD aerosol powder 
formulations are shown in Figure 4. DPPC powders exhibited 
two endothermic phase transitions at 66.9°C and 73.0°C, 
corresponding to the gel-to-ripple bilayer pretransition and 
to the bilayer main transition T
m
 (ie, due to the hydrophobic 
acyl chain melting event) between the rippled gel and liquid 
crystalline phases, respectively.46 DPPG powders showed 
three endothermic phase transitions consisting of two low-
enthalpy pretransitions at ∼55.3°C and ∼79.5°C and a high-
enthalpy main phase transition at 125°C, which correspond 
to the crystal-to-gel bilayer phase transition, gel-to-ripple 
bilayer phase transition, and rippled-to-liquid crystalline 
bilayer main phase transition (T
m
), respectively.46 Co-SD 
aerosol powder formulations of co-SD CsA:DPPC/DPPG 
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Figure 1 Representative scanning electron micrographs of (A) raw unprocessed cyclosporine A and spray-dried cyclosporine A at a (B) 10% pump rate; (C) 25% pump rate; 
(D) 50% pump rate; and (E) 75% pump rate.
Mag: 1000 LV: 10 WD: 30 10 µm Mag: 10000 LV: 10 WD: 30 1 µm Mag: 10000 LV: 10 WD: 30 1 µm
A B C
Figure 2 Representative scanning electron micrographs of (A) raw unprocessed cyclosporine A and cospray-dried cyclosporine A: dipalmitoylphosphatidylcholine/
dipalmitoylphosphatidylglycerol ratio of (B) 25:75 (1:3) and (C) 75:25 (3:1).
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; DPPg, dipalmitoylphosphatidylglycerol; SD, spray dried.
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Figure 3 Representative differential scanning calorimetry thermograms at 
5°C/minute heating scan rate of raw CsA and organic solution advanced SD CsA 
dry powder inhalation aerosol powders.
Notes: 10, 25, 50, and 75 indicate a pump rate of 10%, 25%, 50%, and 75%, 
respectively.





co-SD CsA: DPPC/DPPG 25:75 (1:3)
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Figure 4 Representative differential scanning calorimetry thermograms at 5°C/
minute heating scan rate of raw CsA, pure DPPC, pure DPPg, and organic solution 
advanced co-SD lung surfactant-mimic powders of co-SD CsA:DPPC/DPPg 25:75 
(1:3) and co-SD CsA:DPPC/DPPg 75:25 (3:1).
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; 
DPPg, dipalmitoylphosphatidylglycerol; SD, spray dried.
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25:75 and co-SD CsA:DPPC/DPPG 75:25 compositions 
encapsulated in lung surfactant-mimic DPPC/DPPG (3:1) 
show a bilayer main phase transition temperature (T
m
) at 
72.8°C and 71.1°C, respectively, which are below the indi-
vidual T
m
 values of DPPC and DPPG described above. The 
co-SD aerosol powders did not exhibit a CsA melting peak 
complete miscibility with the phospholipids (ie, no drug-rich 
phase separation was detected).
XRPD
The molecular state of the raw CsA versus SD CsA aerosol 
powder formulations was further evaluated by XRPD to 
measure the degree of molecular order (ie, crystallinity) 
versus molecular disorder (ie, noncrystallinity), which is an 
important physicochemical property for dry powder aerosols. 
In Figure 5, the XRPD diffractogram of raw CsA shows 
sharp diffraction peaks in the range of 5–10 2θ degrees and 
in the range of 14–20 2θ degrees. This indicates a partially 
crystalline powder with defined structural molecular order 
in the solid state that is observed in liquid crystals and 
heteropolypeptides having secondary structure in the solid 
state such as α-helical and/or β-sheet secondary structure 
conformations.30,51 In contrast, the XRPD diffractograms for 
the various SD CsA aerosol powders showed the absence 
of the sharp peaks and the distinctive diffuse “halo” that 
is characteristic of noncrystalline powders suggesting the 
amorphous state of the SD CsA powders. The broad peaks 
in the range of secondary structure conformations of CsA 
are still evident, suggesting the retention of secondary con-
formation following SD.
Diffractograms of the co-SD respirable powders are 
shown in Figure 6. DPPC and DPPG show a distinct peak 
in the range of 20–25 2θ degrees, which is the characteris-
tic range indicative of the solid-state phospholipid bilayer 
structure.52 This characteristic peak is also clearly evident 
in the co-SD CsA:DPPC/DPPG respirable powders, which 
indicates preservation of the solid-state phospholipid bilayer 
structure in these co-SD aerosol powder formulations.
Cross-polarizing light hot-stage microscopy
Figure 7 shows the cross-polarized light optical microscope 
images for the phase transitions of raw CsA at a heating scan 
rate of 5°C/minute, which is the same rate as employed in 
thermal analysis by DSC. Minimal birefringency is detected, 
which agrees with the XRPD diffractogram. At 140.6°C, raw 
CsA exhibited small crystals (Figure 7A). When temperature 
increased to 161.1°C, CsA started to melt (Figure 7B). The 
onset temperature coincided with its melting as measured 
by DSC thermal analysis. Figure 7C shows the liquid state 
of CsA after melting.
Figure 8 shows representative cross-polarized light 
optical microscope images for the phase transitions of SD 
CsA aerosol powders. Various SD batches generated similar 
images to the representative images shown for the SD CsA 
aerosol powder at a 10% pump rate. As shown in Figure 8A, 
SD CsA at a 10% pump rate at 25°C exhibited the complete 
absence of birefringency, which is characteristic of non-
crystalline powders. At 152°C, the aerosol powder started 
to melt (Figure 8C), which was in a good agreement with the 
DSC thermal analysis data of SD CsA at a 10% pump rate 


















Figure 5 Representative X-ray powder diffractograms of raw CsA and various 
organic solution advanced SD CsA aerosol powders.
Notes: 10, 25, 50, and 75 indicate a pump rate of 10%, 25%, 50%, and 75%, respectively.
Abbreviations: CsA, cyclosporine A; SD, spray dried.
















co-SD CsA: DPPC/DPPG 25:75(1:3)
co-SD CsA: DPPC/DPPG 75:25(3:1)
Figure 6 Representative X-ray powder diffractograms of raw CsA, pure DPPC, pure 
DPPg, and organic solution advanced co-SD CsA lung surfactant-mimic powders of 
co-SD CsA:DPPC/DPPg 25:75 (1:3) and co-SD CsA:DPPC/DPPg 75:25 (3:1).
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; 
DPPg, dipalmitoylphosphatidylglycerol; SD, spray dried.
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Figure 7 Representative cross-polarized light optical microscope images of the phase transitions for raw cyclosporine A heated from 25°C to 200°C at 5°C/minute. 
The temperature for each graph is (A) 140.6°C; (B) 161.1°C; and (C) 197.1°C.
Note: Scale bar represents 0.2 mm.
Figure 8 Representative cross-polarized light optical microscope images for the phase transitions of spray-dried cyclosporine A at a 10% pump rate. The samples were 
heated from 25°C to 200°C at 5°C/minute. The temperature for each graph is (A) 25°C; (B) 146.8°C; (C) 152°C; and (D) 188°C.
Note: Scale bar represents 0.2 mm.
(Figure 4). At 188°C, SD CsA at a 10% pump rate existed 
completely as a liquid (Figure 8D).
CD spectroscopy
Figure 9 shows the CD spectrum of CsA at 25°C in methanol. 
The distinct pattern observed in the CD spectrum clearly 
indicates the presence of secondary structure, suggesting 
the presence of an α-helix conformation. This makes sense 
given the polypeptide structure of CsA.
Karl Fischer coulometric titration
The residual water content values for all one-component CsA 
powders were quantified analytically by Karl Fischer coulo-
metric titration and are shown in Table 4. The residual water 
content before SD for raw CsA was 1.64%, which is low as 
would be expected due to the hydrophobic nature of CsA. 
After advanced organic solution SD from the alcohol metha-
nol, the value was further reduced to remarkably low levels 
that are well within recommended levels for DPIs. Moreover, 
the extent of remarkable reduction in the residual water per-
centage in the aerosol powders depended on the pump rate. 
At the lowest SD pump rate used in these  experiments of 
10% (ie, slowest SD process), SD CsA had the lowest water 
content (0.7%), and water content was increased with each 
increment in the percentage of pump rate used in the SD 
process. When a higher pump rate of 75% was used (ie, faster 
SD process), the SD sample had a residual water content of 
1.60%, which is still low and similar to that measured in raw 
CsA. These results are in good agreement with the data from 
the gravimetric vapor sorption analysis (Figure 10).
Low residual water content also existed in the multifunc-
tional co-SD CsA lung surfactant-mimic aerosol formulations. 
Before SD, the mean values of water content of raw CsA, 
DPPC, and DPPG were 1.64%, 1.95%, and 0.51%, respec-
tively (Table 5). After organic solution advanced SD, the 
residual water content of co-SD CsA:DPPC/DPPG lung sur-
factant-mimic aerosol powder formulation was reduced further 
to ∼1.1% (lower than that of raw CsA and raw DPPC), which 
is favorable for superior DPI aerosolization and is well within 
the recommended levels for dry powders. Low water content 
in aerosol powders is important for pharmaceutical stability 
and improved aerosol dispersion performance.23,24,26,40,42
gravimetric water vapor sorption
Figure 10 shows the water vapor absorption isotherms for 
raw CsA and SD CsA aerosol powders produced at various 
SD pump rates. These profiles show that the hydrophobic 
nature of CsA appears to dominate its low water vapor uptake 
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Table 4 Water content (weight change percentage) by Karl Fisher 
titration for raw cyclosporine A and spray-dried cyclosporine A 
powders at various spray drying pump rates
Sample Water content, %
Raw CsA 1.64 ± 0.08
SD CsA 10%P 0.70 ± 0.33
SD CsA 25%P 1.00 ± 0.08
SD CsA 50%P 1.33 ± 0.16
SD CsA 75%P 1.60 ± 0.24
Notes: Mean ± standard deviation, n = 3.
Abbreviations: %P, pump rate; CsA, cyclosporine A; SD, spray dried.
Wavelength, λ,nm 

















Figure 9 Representative circular dichroism (m°) spectrum of cyclosporine A at 
25°C in methanol.
in the solid state for the raw and SD CsA aerosol powders. 
These isotherms are in good agreement with Karl Fisher 
values, which also revealed low residual water content in all 
powders under ambient RH conditions. This is favorable for 
enhanced aerosol dispersion performance as DPIs.23,24,26,40,42 
Indeed, these are high performing aerosols as DPIs (to be 
discussed).
The maximal absorption weight change percentage 
values for SD CsA aerosol powders at high lung RH levels 
modeled at 90% and 93% RH are shown in Table 5. This 
is the maximal water percentage absorbed by the respirable 
powders at these very high RH levels, which is low and as 
expected for hydrophobic powders.
For co-SD CsA:DPPC/DPPG 25:75 and co-SD 
CsA:DPPC/DPPG 75:25, the rate of water vapor absorp-
tion isotherms remained relatively similar to one another at 
all RH levels (Figure 11). The maximal absorption weight 
change percentage values at high lung RH levels modeled at 
90% and 93% RH are stated in Table 6. The maximal water 
percentage absorbed at 90% RH and 93% RH reveals that 
DPPC dominates the maximal values for the co-SD CsA 
lung surfactant-mimic aerosol powders. This property may 
aid in improving wettability, spreading, and absorption in 
the lungs. DPPC bilayers undergo a lyotropic phase transi-
tion in the solid state from the gel to the liquid crystal at RH 
values greater than 75%, as reported earlier.46 Sodium DPPG 
absorbed much less water due to its tightly packed bilayer 
as a result of favorable electrostatic interactions between the 
cationic sodium ion and anionic polar headgroup, which is 
in good agreement with an earlier report.46 At intermediate 
RH regions, the weight change percentage of DPPG showed 
a plateau with an increasing RH between 20%–70% but 
increased significantly when the RH exceeded ∼70%. The 
plateau region is indicative of a crystal-to-gel bilayer lyo-
tropic phase transition, as reported earlier.46
In vitro aerosol dispersion performance 
by the NgI
Figure 12 shows the DPI aerosol dispersion and deposition 
profile for novel SD CsA DPI aerosols and multifunctional 
co-SD CsA:DPPC/DPPG lung surfactant-mimic DPI aero-
sols aerosolized using a United States (US) Food and Drug 
Administration (FDA)-approved DPI device, the Handi-
Haler. As seen in Figure 12, measurable deposition is present 
on all stages including the lowest stages of stages six and 
seven. Outstanding deposition on stages modeled for middle 
lung and deep lung delivery is present for all DPI aerosols. 
Distinct trends are seen in SD pump rate effect on tailoring 
the aerosol deposition patterns for SD CsA aerosols. Namely, 
the SD CsA powders produced at the lower SD pump rates 
of 50% and 25% appear to give increased aerosol deposi-
tion on the lower NGI stages, which are modeled to predict 
deeper lung delivery.  Specifically, at a 75% pump rate, the 
aerosol deposition peak mode is on stage three, while the 
aerosol deposition peak mode is on stage four for aerosols 
engineered at a 50% pump rate and 25% pump rate. The 
aerosol peak mode for all co-SD CsA:DPPC/DPPG lung 
surfactant-mimic DPI aerosols is on stage four, with higher 
deposition than SD CsA aerosols on stage four.
Table 7 shows the aerosol performance parameters for 
the novel SD CsA DPI aerosol powders and the co-SD CsA 
lung surfactant-mimic DPI aerosol powders. The ED  values 
are very high in the range of ∼80%–85% and represent effi-
ciency in aerosolization for SD CsA aerosols. The ED values 
for co-SD CsA lung surfactant-mimic DPI aerosol powders 
are even higher, suggesting that the presence of DPPC/
DPPG lung surfactant favorably enhances the aerosolization 
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Figure 10 gravimetric water vapor absorption isotherms for (A) raw cyclosporine A and spray-dried cyclosporine at a (B) 10% pump rate; (C) 25% pump rate; (D) 50% 
pump rate; and (E) 75% pump rate.
Table 5 Residual water content (weight change percentage) of 
raw cyclosporine A, lung surfactant-mimic phospholipids (dipalmi-
toylphosphatidylcholine and dipalmitoylphosphatidylglycerol), and 
cospray-dried cyclosporine A: dipalmitoylphosphatidylcholine/ 
dipalmitoylphosphatidylglycerol inhalation powders before and 
after organic solution advanced cospray drying
Sample Water content, %
Raw CsA 1.64 ± 0.10
DPPC 1.95 ± 0.45
DPPg 0.51 ± 0.77
co-SD CsA:DPPC/DPPg 25:75 (1:3) 1.16 ± 0.37
co-SD CsA:DPPC/DPPg 75:25 (3:1) 1.12 ± 0.52
Notes: Mean ± standard deviation, n = 5.
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; 
DPPg, dipalmitoylphosphatidylglycerol; SD, spray dried.
efficiency process. This makes sense as these phospholipids 
are inherently surface active and can reduce interparticulate 
interactions, which will enhance dispersion of DPI aerosols. 
The values of RF are very high in the range of ∼90%–95% 
for SD CsA aerosols and similarly very high for the co-SD 
CsA:DPPC/DPPG lung surfactant-mimic dry powder aero-
sols. The values of FPF are also remarkably high at ∼50% 
for SD CsA aerosols. These high FPF values are significantly 
greater than the ∼10%–20% that is often observed for com-
mercially marketed pharmaceutical inhalation aerosol prod-
ucts.53,54 The MMAD values are in the optimal size range of 
2.5–3 µm for all aerosol powders, which is optimal for high 
lung deposition targeting the smaller airways.




Cyclosporine A dry powder inhalers
International Journal of Nanomedicine 2013:8
Relative humidity (%)

























Figure 11 gravimetric water vapor absorption isotherms for raw CsA, pure DPPC, 
pure DPPg, and organic solution advanced co-SD CsA:DPPC/DPPg dry powder 
formulations of “CsA lipo 25:75” for co-SD CsA:DPPC/DPPg 25:75 (1:3) and “CsA 
lipo 75:25” for co-SD CsA:DPPC/DPPg 75:25 (3:1).
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; 
DPPg, dipalmitoylphosphatidylglycerol; lipo, lipospheres; SD, spray dried.
Table 6 The maximal weight change percentages by water 
absorption at 90% and 93% relative humidity for raw versus 
cospray-dried cyclosporine A: dipalmitoylphosphatidylcholine/
dipalmitoylphosphatidylglycerol particles for dry powder 
inhalation aerosol powder formulations
Sample wt% at 90% RH wt% at 93% RH









Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; 
DPPg, dipalmitoylphosphatidylglycerol; RH, relative humidity; SD, spray dried; wt%, 
weight change percentage.
Discussion
In this systematic and comprehensive study, novel SD CsA 
DPIs and multifunctional co-SD CsA:DPPC/DPPG lung 
surfactant-mimic DPIs were rationally designed and success-
fully produced. Respiratory delivery of CsA incorporated in 
biocompatible biodegradable DPPC/DPPG in the solid state 
as DPI aerosols would facilitate CsA delivery with high local 
concentration in the smaller airways of the lung.  Additionally, 
these high-performing DPI aerosols are multifunctional 
and have nanomedicine properties associated with the lung 
surfactant-mimic phospholipids – DPPC/DPPG – for targeted 
pulmonary nanomedicine. In addition, improved absorption 
due to improved wettability may be offered by the presence 
of these phospholipids. Novel organic solution advanced SD 
particles and co-SD lung surfactant-mimic particles all were 
successfully designed under a rationally chosen advanced SD 
closed mode condition with the primary particle size below 
5.0 µm and aerosol deposition on the lower stages of the NGI 
all the way to the lowest NGI stage seven.
All aerosol powder formulations were unimodal with 
a narrow size distribution. All SD CsA powders appeared 
to be amorphous based on the XRPD data. The SD CsA 
powders produced at the lower SD pump rates of 50% and 
25% appeared to provide increased aerosol deposition on 
the lower NGI stages, which are modeled to predict deeper 
lung delivery. Specifically, at a 75% pump rate, the aerosol 
deposition peak mode is on stage three, while the aerosol 
deposition peak mode is on stage four for aerosols engineered 
at a 50% and 25% pump rate. The aerosol peak mode for all 
co-SD CsA:DPPC/DPPG lung surfactant-mimic DPI aerosols 
is on NGI stage four, with higher deposition than SD CsA 
aerosols on NGI stage four.
SD is a commonly used method in the preparation of 
inhalation powders.55,56 To tailor and optimize the particle 
characteristics, the SD operating parameters can be modi-
fied and include solvent type (organic or aqueous), solute 
concentration, atomization pressure, feed properties, pump 
rate, gas type, airflow, and drying temperature.22,27,57 In this 
study, pure alcohol solutions were used in organic solution 
SD and co-SD in closed mode to effectively reduce both the 
residual water content and particle size due to its nonaqueous 
nature and lower surface tension. In addition, the specific 
method reported here enables high-throughput  optimization. 
Compared to water’s high surface tension (72 mN/m), alco-
hols such as methanol (which are also regarded as “green 
chemicals”) have a much lower surface tension in the range 
of 22—25 mN/m. It is observed that rationally choosing the 
SD pump rate enabled tailoring of the respirable article size 
and particle surface morphology, which provided excellent 
dispersion as dry powder aerosols and resulted in high aerosol 
performance values for all SD and co-SD aerosol formula-
tions in this study.
Preservation of the phospholipid bilayer structure in the 
solid state following organic solution SD in closed mode 
was successfully achieved for all co-SD CsA:DPPC/DPPG 
powders, as confirmed by XRPD and DSC. The small particle 
size, unimodal narrow size distribution, particle morphology, 
surface morphology, and very low residual water content of 
all co-SD aerosol formulations were all suitable for targeted 
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Table 7 Aerosol dispersion performance properties of aerosolized dry powders including emitted dose, fine particle fraction, respirable 
fraction, mass median aerodynamic diameter, and geometric standard deviation for inhalable microparticle/nanoparticle formulations 
of spray-dried cyclosporine A and cospray-dried cyclosporine A: dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylglycerol 
dry powder inhalation aerosol systems
Dry powder inhalation aerosol system Aerosol performance parameters
SD and co-SD powders ED, % FPF, % RF, % MMAD, μm GSD
SD CsA 25%P 81.10 ± 9.29 49.52 ± 3.25 91.35 ± 8.59 2.18 ± 0.09 1.77 ± 0.03
SD CsA 50%P 79.00 ± 4.39 51.22 ± 3.15 96.14 ± 1.30 2.26 ± 0.06 1.71 ± 0.02
SD CsA 75%P 85.21 ± 5.57 52.14 ± 12.48 95.82 ± 1.36 2.75 ± 0.47 1.79 ± 0.19
co-SD CsA:DPPC/DPPg 25:75 (1:3) 89.06 ± 1.69 39.09 ± 1.40 84.08 ± 0.74 3.01 ± 0.05 2.16 ± 0.06
co-SD CsA:DPPC/DPPg 50:50 (1:1) 83.12 ± 1.46 48.42 ± 3.83 94.55 ± 1.00 2.57 ± 0.04 1.86 ± 0.04
co-SD CsA:DPPC/DPPg 75:25 (3:1) 85.40 ± 1.04 52.99 ± 4.12 96.15 ± 8.65 2.79 ± 0.47 1.85 ± 0.05
Notes: Mean ± standard deviation, n = 3.
Abbreviations: %P, pump rate; CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; DPPG, dipalmitoylphosphatidylglycerol; ED, emitted dose; FPF, fine particle 
fraction; gSD, geometric standard deviation; MMAD, mass median aerodynamic diameter; RF, respirable fraction; SD, spray dried.
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Figure 12 Therapeutic aerosol dispersion performance of dry powder inhalers as percentage deposition on each stage of the NGI at an airflow rate (Q) of 60 L/minute for 
SD CsA and co-SD CsA:DPPC/DPPG DPI aerosol systems. For the NGI at Q = 60 L/minute, the NgI stage cutoff diameters are as follows: stage one (8.06 µm), stage two 
(4.46 µm), stage three (2.82 µm), stage four (1.66 µm), stage five (0.94 µm), stage six (0.55 µm), and stage seven (0.34 µm).
Abbreviations: CsA, cyclosporine A; DPPC, dipalmitoylphosphatidylcholine; DPPg, dipalmitoylphosphatidylglycerol; NgI, next generation impactor; P, pump rate; 
SD, spray dried.
respiratory drug delivery. Organic solution advanced SD in 
closed mode enabled all aerosol powders to have remarkably 
low residual water content which enhanced aerosol dispersion 
performance, as reflected in remarkably high ED percentage, 
RF percentage, and FPF percentage aerosol parameter values. 
The MMAD values were in the optimal range of 2.5–3 µm 
for targeting the smaller airways.
Excellent aerosol dispersion performance was demon-
strated using the NGI coupled with the HandiHaler DPI 
device, which clearly indicated that the formulated par-
ticles would be optimal for targeted delivery as aerosolized 
powders. This demonstrates for the first time the significant 
potential of these various advanced DPI aerosols (designed 
and optimized by organic solution advanced SD in closed 
mode) to be utilized to effectively deliver SD CsA alone 
and with lung surfactant-mimic phospholipids – DPPC/
DPPG – for targeted lung transplant immunosuppression 
with multifunctional properties as DPI aerosols.
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Conclusion
Novel DPI aerosol formulations of CsA for pulmonary 
delivery were rationally designed and successfully developed 
by the novel particle engineering design process technology 
of organic solution advanced SD from alcohol solutions 
at several rationally chosen pump rates. All DPI SD CsA 
aerosol powders had excellent physicochemical properties 
with optimal particle morphology, surface morphology, 
and very low residual water content. The aerosol dispersion 
parameters of ED, FPF, and RF were all high. The MMAD 
values were low and in the optimal range for targeting the 
smaller airways.
In addition, co-SD multifunctional dry powder aerosols 
consisting of co-SD CsA:DPPC/DPPG showed excellent 
physicochemical and aerosol dispersion properties as high-
performing DPIs with very low residual water content. 
The phospholipid bilayer structure was preserved in the 
solid state, as confirmed by DSC and XRPD analyses. As 
reported here, the DPI aerosol delivery systems of SD CsA 
and co-SD CsA:DPPC/DPPG have the potential to signifi-
cantly reduce the side effects associated with the systemic 
exposure of CsA, leading to a wider therapeutic safety 
margin and enhanced patient outcomes/quality of life in 
lung transplant patients.
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